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Background/Purpose: The aim of the present study is to validate the Chinese version 8-item Morisky
medication adherence scale (MMAS-8) in patients with type 2 diabetes mellitus (T2DM).
Methods: A cross-sectional survey was conducted. After translation, a convenience sample of 182 pa-
tients with T2DM complete the Chinese version MMAS-8, and medication adherence visual analogue
scale. The intraclass correlation coefﬁcient and Cronbach a were calculated to determine reliability and
internal consistency, respectively. Validity was conﬁrmed using convergent, known group, and construct
validity.
Results: The internal consistency determined by Cronbach a was 0.65. Testeretest reliability expressed
by intraclass correlation coefﬁcient was 0.80. A positive correlation was observed between Chinese
version MMAS-8 and medication adherence visual analogue scale (r ¼ 0. 75, p < 0.01). A signiﬁcant
relationship between MMAS-8 categories and HbA1c categories (c2 ¼ 21.63; p < 0.001) was found. Factor
analysis showed that the MMAS had two dimensions: forgetting to take medications and the complexity
of drug regimen; and stopping medication.
Conclusion: The Chinese version of the MMAS-8 is a reliable and valid measure of medication adherence
that can now be used in type 2 diabetic patients.
Copyright  2013, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
LLC.
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Diabetes mellitus (DM) is a major health problem with a
growing prevalence and high rates of morbidity and mortality. The
International Diabetes Federation has concluded that there will be
380 million individuals with diabetes in 2025.1 In China, a recent
study showed that the prevalence of the type 2 DM (T2DM) in
adults aged 20 years is now 9.7%.2 It is recognized by the World
Health Organization as one of the world’s most important public
health problems for prevention, diagnosis, and treatment.
Diabetes can be treated by effective medications. Successful
blood glucose control could decrease the morbidity and mortality
resulting from T2DM complications that place a considerable
ﬁnancial burden on society.3,4 Although there are many factors that
affect glycemic control among patients with diabetes, it is known to
be improved by adherence to DM medications, and treatmentrch Center, Jiangsu Province
o).
linical Gerontology & Geriatrics. Putility is limited by poor adherence.5e7 Adherence is deﬁned as “the
extent to which a person’s behaviordtaking medication, following
a diet and/or executing lifestyle changesdcorresponds with agreed
recommendations from the healthcare provider.”8 Several studies
have shown that the medication adherence in type 2 diabetic pa-
tients ranges from 36% to 93%.5,7 Cramer9 has pointed out that
many diabetic patients take less than the prescribed amounts of
their medications. Poor adherence compromises safety and treat-
ment effectiveness, leading to increasing mortality and morbidity
with considerable direct and indirect costs to the healthcare
system.10,11
Improving adherence to diabetes treatment thus is a vital public
health issue. Achieving this requires appropriate tools to measure
adherence that can be used tomonitor improvements. Tools used to
measure adherence include pill counts, electronic monitoring sys-
tems, monitoring of drug concentrations in blood and urine,
medication records, and self-reports.12 But the most convenient,
least expensive, and easiest way to assess medication adherence is
self-reporting. Morisky et al13 developed a four-item self-report
questionnaire to assess medication adherence, which is widely
used but has shown poor psychometric properties. Recently, an
eight-item Morisky medication adherence scale (MMAS-8) hasublished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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the previous four-item scale.
Although the MMAS-8 has been validated in other lan-
guages,15,16 this questionnaire has not been translated into Chinese.
Thus, the goal of the present study was to verify the reliability and
validity of the Chinese version MMAS-8 among patients with
T2DM.
2. Methods
2.1. Participants
For this validation study, 182 outpatients from the Diabetic Care
and Research Center of Jiangsu Province Geriatric Institute were
consecutively recruited from May 2012 to September 2012. Inclu-
sion criteria were: (1) patients had been diagnosed with T2DM at
least 1 year earlier; (2) patients use antidiabetes medications; and
(3) patients are able to communicate in the Chinese language. Pa-
tients who met all three criteria were included. Patients who had
severe health problems or cognitive impairments and could not
complete interviews were excluded. Informed consent was ob-
tained from each participant prior to entering the study and the
study was approved by the ethics committee of Jiangsu Province
Geriatric Institute.
2.2. Data collection
The data on demographic and clinical characteristics of partic-
ipants was collected. All patients were asked to complete the Chi-
nese version of MMAS-8 and Adherence Visual Analogue Scale
(MA-VAS). A sample of 41 patients selected randomly ﬁlled out the
MMAS-8 again after 30 days.
The following data on demographic and clinical characteristics
were compiled: age, sex, height and weight (for body mass index
calculation), education, duration of diabetes, and hemoglobin A1C
(HbA1c). DMwas deﬁned as fasting glycemic values126mg/dL, or
with a previous diagnosis and use of medication for the treatment
of diabetes.17
The Chinese version MMAS-8 was translated according to Bea-
ton’s guidelines for the process of translation and cross-cultural
adaptation of self-report measures.18 The Chinese version MMAS-
8 was independently translated into Chinese by two bilingual
translators with the Chinese mother tongue and then translated
back by two native English-speaking translators. Inconsistencies in
translation among translators were resolved by discussion. A re-
view committee was formed to examine the translations, then the
Chinese version MMAS-8 was developed, which was culturally
applicable and reﬂected the intent of the instrument.
The Chinese version MMAS-8, a self-administered rating scale
for assessing medication adherence, contains eight items. Each
item is measuring a speciﬁc behavior and is not a determinant of
adherence behavior.19 Response choices are yes/no for items 1e7
and a 5-point Likert response for the last item. Each response of
“no” is rated as “1” and each “yes” is rated as “0” except for Item 5,
inwhich each response of “yes” is rated as “1” and each “no” is rated
as “0”. For Item 8, if a patient chooses response “0”, the score is “1”
and if they choose response “4”, the score is “0”. Responses “1”, “2”,
and “3” are rated as “0.25”, “0.75”, and “0.75”, respectively. The total
score on the MMAS-8 can range from 0 to 8, where higher scores
indicate higher adherence. The degree of adherence was deter-
mined according to the score resulting from the sum of all the
correct answers: low adherence (<6 points), medium adherence (6
to <8 points), and high adherence (8 points). In this study, patients
were considered adherent when they had a score equal to eight in
the MMAS-8.The medication adherence visual analogue scale (MA-VAS) is
another self-reported instrument for assessing medication adher-
ence.20 For this, a respondent is shown a line with endpoints of “no
medication adherence at all” at 0 and “full medication adherence”
at 10.
2.3. Measurements
A test is useful when it measures what it is intended to measure
(validity) and when the results stay consistent across repeated
measurements over time (reliability).
To determine the reliability of theMMAS-8, internal consistency
and testeretest reliability were calculated. In this study, a second
Chinese version MMAS-8 was administered to the subsample
selected randomly 30 days later for testeretest reliability; a period
long enough not to remember the exact answers from the ﬁrst time
and short enough not to expect a therapy effect.21
Validity was determined by measuring the convergent, known
group, and construct validity.
Convergent validity was evaluated using Spearman’s correlation
coefﬁcients to assess the association between the MMAS-8 and
MA-VAS. Known group validity was assessed through the associa-
tion of MMAS-8 categories (high, medium, and low adherence) and
A1C levels (7% and <7%). Construct validity was tested using an
exploratory factor analysis.
2.4. Statistical analysis
Descriptive statistics were used to describe demographic and
clinical characteristics of patients and their medication adherences
scores. Percentages and frequencies were used for the categorical
variables, whereas means and standard deviations were calculated
for the continuous variables. The characteristics of the whole
sample and of the adherent groups were presented. The Chi-
square (c2) test was employed for categorical variables and anal-
ysis of variance (ANOVA) tests were used to evaluate the differ-
ences between three adherent groups. Cronbach a was employed
to evaluate internal consistency. Testeretest reliability was
assessed with the intraclass correlation coefﬁcient (ICC) of abso-
lute agreement based on a two-way mixed model.22 The criterion
for accepting Cronbach a is a score above 0.5.23,24 The criteria for
interpretation of ICCs are based on Rosner (suggesting that ICC
<0.40 ¼ poor agreement, ICC 0.40e0.75 ¼ fair to good agreement,
ICC  0.75 ¼ excellent agreement).25
Convergent validity was assessed using Spearman rank corre-
lation between MMAS-8 and MA-VAS using Spearman’s rho. Cor-
relations were interpreted using the following criteria: 0e
0.25 ¼ little or no correlation; 0.25e0.5 ¼ fair correlation; 0.5e
0.75 ¼ moderate to good correlation; and >0.75 ¼ very good to
excellent correlation.25 Known group validity was assessed through
the association of HbA1c levels (7% and <7%) and MMAS-8 cat-
egories using c2 tests. The factor analysis evaluating construct
validity was conducted by a principal component analysis, followed
by Varimax rotation with Kaiser normalization. Kaiser’s eigenvalue
>1 was used to determine the number of factors. Factor loadings
>0.4 on each itemwere considered to belong to the corresponding
factors.26
The signiﬁcance of the statistical tests was set at 0.05. Statistical
analysis was performed with SPSS version 16.0 for windows.
3. Results
Baseline demographic and clinical characteristics of the total
and adherent groups are shown in Table 1. Of the 182 patients with
T2DM, 49 (26.9%), 76 (41.8%), 57 (31.3%) were in the low, medium,
Table 3
Exploratory factor analysis of the Chinese version 8-item Morisky medication
adherence scale in patients with type 2 diabetes (n ¼ 182).
Item Factor 1 Factor 2
1. Sometimes forget to take medications? 0.672 0.121
2. Over the past 2 weeks, were there any 0.644 0.167
Table 1
Demographic and clinical characteristics of the participants (n ¼ 182).
Characteristics Total (n ¼ 182) Low adherence (n ¼ 49) Medium adherence (n ¼ 76) High adherence (n ¼ 57) F/c2 P
Age (y) 64.90  9.57 61.30  10.70 65.70  8.23 66.93  9.53 5.24 0.006
Female 72.5 71.4 67.1 80.7 3.06 0.216
BMI (kg/m2) 24.24  4.30 24.39  4.22 24.34  4.03 24.00  4.73 0.135 0.874
Education level
Primary and below 3.8 4.1 1.3 7.0 3.84 0.428
Secondary school 34.6 30.6 39.5 31.60
College and above 61.5 65.3 59.2 61.40
Diabetic duration (y) 8.29  6.43 7.41  5.88 9.00  6.29 8.09  7.04 0.95 <0.001
HbA1c 6.74  0.84 7.12  0.86 6.73  0.88 6.42  0.64 10.12 <0.001
MA-VAS score 8.75  1.30 7.65  1.49 8.95  1.01 9.41  0.77 35.89 <0.001
MMAS-8 score 6.46  1.54 4.42  1.14 6.64  0.55 8.00  0.00 360.69 <0.001
Data are presented as % or mean  SD, unless otherwise indicated.
BMI ¼ body mass index; MA-VAS ¼ adherence visual analogue scale; MMAS-8 ¼ 8-item Morisky medication adherence scale.
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were found in age, HbA1c levels, duration of diabetes, MA-VAS
score, and MMAS-8 score (p < 0.05). No signiﬁcant differences
were observed among the three groups in terms of sex, body mass
index, and educational level.
3.1. Reliability
The a coefﬁcients were 0.65 for the Chinese version MMAS-8,
which is below 0.7 but higher than 0.5.23,24 The ICC determining
the testeretest reliability was 0.8, which indicates the high stability
of the Chinese version MMAS-8.
3.2. Convergent validity
MMAS-8 was positively associated with the MA-VAS (r ¼ 0.75,
p < 0.01).
3.3. Known group validity
As shown in Table 2, a signiﬁcant relationship betweenMMAS-8
categories and HbA1c categories (c2 ¼ 21.63, p < 0.001) was found.
Around 37.6% (47/125) of the low adherence patients were in the
poor glycemic control group, while 82.5% (47/57) of those in the
high adherence group were in the good glycemic control group.
3.4. Construct validity
Exploratory factor analysis showed two factors with eigenvalues
>1, which explained 45.4% of the total variance. Factor loadings
between the eight items of MMAS-8 and the two factors are pre-
sented in Table 3. Factor 1 comprised Items 1, 2, 4, 7, and 8, which
mostly involved patients forgetting to take medications and the
complexity of the drug regimen. Factor 2 consisted of Items 3, 5,Table 2
The relationship between MMAS-8 and blood glucose control (n ¼ 182).
HbA1c  7%
(poor control)
HbA1c < 7%
(good control)
c2 p
Low adherence
(MMAS < 6)
28 (57) 21 (43) 21.630 0.000
Medium adherence
(MMAS 6e8)
19 (25) 57 (75)
High adherence
(MMAS ¼ 8)
10 (18) 47 (82)
Data are presented as n (%).
MMAS-8 ¼ 8-item Morisky medication adherence scale.and 6, which were viewed as patients stopping medications when
they were feeling better or worse.4. Discussion
The main aim of this paper was to report the reliability and
validity of the translated version of the MMAS-8 in patients with
diabetes. This study was the ﬁrst to systematically translate and
validate the eight-item MMAS into the Chinese language. Other
studies evaluate the MMAS-8 in diabetes patients in Thailand and
in Malaysia.15,16 The original MMAS-8 was tested by Morisky et al14
on a sample of hypertensive patients, and it was found that the
scale was reliable with good predictive validity. The Malaysian
study among Malaysian patients with diabetes showed that the
MMAS-8 had good testeretest reliability with good convergent
validity.15 The Thailand study showed that the MMAS-8 had good
convergent validity with good testeretest reliability in Thai pa-
tients with T2DM.16 Our study demonstrates that the Chinese
version MMAS-8 had good testeretest reliability with good
convergent validity.
As for reliability, the Chinese version MMAS-8 had excellent
testeretest reliability (ICC ¼ 0.80), whereas internal consistency
reliability was moderate (Cronbach a¼ 0.65). Our result is different
from that of Morisky et al.14 They reported that the MMAS-8 had a
Cronbach a of 0.83. But our result is consistent with the Thailand
and Malaysian studies.15,16 An explanation for the unacceptable a
value in our study is that sample size was smaller than the sampledays when you did not take your diabetes medicine?
3. Have you ever cut back or stopped taking
your medication without telling your doctor
because you felt worse when you took it?
0.148 0.684
4. When you travel or leave home, do you
sometimes forget to bring along your medications?
0.552 0.110
5. Did you take your diabetic medicine yesterday? 0.106 0.775
6. When you feel like your diabetes is
under control, do you sometimes stop
taking your medicine?
0.344 0.430
7. Taking medication every day is a real
inconvenience for some people.
Do you ever feel hassled about sticking
to your diabetes treatment plan?
0.663 0.102
8. How often do you have difﬁculty
remembering to take all your diabetes medication?
0.728 0.141
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relation coefﬁcient and the sample size can affect the result.27
Another explanation of the lower a value is that most of the
items on the scale use a binary response (yes/no), and if more
response choices were applied like the ﬁve-level Likert scale, the a
value would improve because the lower measurement error is
associated with more response options.28
For validity, three aspects are considered: convergent validity,
known group validity, and construct validity. In the present study,
Chinese version MMAS-8 was associated with MA-VAS, thus con-
ﬁrming the convergent validity. These results corroborate the re-
sults obtained by other MMAS-validation studies.15,16 As for
known-groups validity, although therewas a signiﬁcant association
between the Chinese version MMAS-8 results and blood glucose
control (c2 ¼ 21.63; p < 0.001), indicating that the instrument was
able to differentiate between patients whowere clinically different.
Glycemic control represented by HbA1c was found to be signiﬁ-
cantly related with MMAS-8 scores, in which lower HbA1c (better
glycemic control) was associated with higher adherence scores. As
for construct validity, two known-groups mensional scales were
shown. It is different from the study results of Morisky et al,14 but
similar to that of Sakthong et al.16 This kind of scale multidimen-
sionality may be another explanation for the a value in our study.
In conclusion, the ﬁndings of this study provide initial support
for the reliability and validity of the Chinese version MMAS-8. The
Chinese version MMAS-8 is a valid and reliable instrument for
assessing medication adherence in patients with T2DM. Further
testing of the measure is needed with a larger, more diverse group
of patients across different Chinese sociocultural contexts and pa-
tients with different diseases. In the future, studies aiming to
investigate if the Chinese version MMAS-8 is able to detect the
effect of intervention should also be conducted.References
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